Related Experiment Video
Updated: Oct 13, 2025
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
Published on: September 27, 2024
Use of a Benchmark Tracking Assessment to Support Expansion of Buprenorphine for Treatment of Opioid Use Disorder in
Andrew L Sussman1, Jennifer N Crawford2, Heidi Rishel Brakey2
1From the Department of Family and Community Medicine and University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, Albuquerque (ALS); Department of Psychiatry & Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque (JNC); Clinical and Translational Science Center, University of New Mexico Health Sciences Center, Albuquerque (HRB); Department of Psychiatry & Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque (RSA); Department of Family and Community Medicine, University of New Mexico Health Sciences Center, Albuquerque (OBM); Department of Psychiatry & Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque (VJ, SB, JS). asussman@salud.unm.edu.
Introduction:
Barriers to the expansion of opioid use disorder (OUD) treatment in primary care using buprenorphine are well documented. Providers require support along a continuum. A systematic tracking framework to enhance provider progress along this continuum is lacking.
Methods:
We developed a benchmark tracking assessment (BTA) as part of data collection in a 5-year study to examine the impact of provider participation in an online intervention to support expansion of buprenorphine treatment for OUD in rural primary care. Providers were contacted via phone every 3 months for up to 2 years to track their advancement along the 5 identified key benchmarks and were offered support for any barriers encountered.
Results:
Forty-one providers enrolled in the study. Almost half (49%) did not experience a barrier that prevented them from accomplishing their next benchmark. Of the remaining 51% of providers, the majority (75%) experienced barriers early in the training and licensure phases, with most citing lack of time as the main reason.
Conclusion:
The BTA offers a feasible approach to identifying challenges along the training to prescription continuum and facilitated targeted support to address barriers. This framework has the potential, with locally contextual adaptations, to guide medication-assisted treatment implementation and training efforts.
More Related Videos
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
01:25Analgesia and Pain Management
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:16Therapeutic Drug Monitoring: Overview and Classification